TY - JOUR A2 - Rosivall, Laszlo AU - Takami, Hiroya AU - Washio, Kazunori AU - Gotoh, Hiromichi PY - 2017 DA - 2017/08/22 TI - Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study SP - 6218129 VL - 2017 AB - Denosumab increases bone mineral density (BMD) in patients not receiving hemodialysis therapy. However, limited data are available in the literature concerning the use of denosumab in hemodialysis patients. We treated male hemodialysis patients with low radius BMD with denosumab therapy for 1 year and evaluated its effect on radius BMD. Seventeen patients were treated with denosumab 60 mg every 6 months, and 20 patients were not treated with denosumab (control group). At seven days, the mean corrected calcium level decreased from 9.2±0.5 mg to 8.5±0.5 mg (P<0.01), and mean serum phosphorus decreased from 5.0±1.3 mg/dl to 4.2±0.9 mg/dl (P<0.01). At 1 month, the corrected calcium and serum phosphorus levels were 9.2±0.9 mg/dl and 4.0±1.1 mg/dl, respectively. At 1 year, BMD increased by 2.6%  ± 4.4% in the denosumab group and decreased by 4.5%  ± 7.7% in the control group (P<0.001). In our observational study, denosumab therapy represents an effective treatment for male dialysis patients with low BMD. SN - 2090-214X UR - https://doi.org/10.1155/2017/6218129 DO - 10.1155/2017/6218129 JF - International Journal of Nephrology PB - Hindawi KW - ER -